Vulvovaginal Candidiasis Treatment Market Size, Demand, Growth, Challenges and Future Trends: SPER Market Research

Q: How can I get the sample report on the Vulvovaginal Candidiasis Treatment Market?

You can get the sample pages by clicking the link - Click Here

Published: Dec 2022	Report ID: PHAR2214	Pages: 1 - 239	Formats^*:
Category : Pharmaceutical

Vulvovaginal Candidiasis Treatment Market Introduction and Overview

According to SPER Market Research, the Global Vulvovaginal Candidiasis Treatment Market is estimated to reach USD 1.62 billion by 2032 with a CAGR of 4.61%.

The report includes an in-depth analysis of the Global Vulvovaginal Candidiasis Treatment Market, including market size and trends, product mix, applications, and supplier analysis. Treatment for vulvovaginal candidiasis mostly consists of antifungal drugs, which can be taken orally or as topical creams. Healthcare providers frequently suggest over-the-counter antifungal creams like clotrimazole and miconazole or prescription oral drugs like fluconazole. By getting rid of the extra yeast, these antifungal medications relieve painful symptoms like itching. Known medically as candidal vaginitis or candidal vulvovaginitis, vaginal yeast infections are a common fungal illness. Symptoms of the infection include swelling, rashes, redness, and itching, as well as burning or discomfort during urination or sexual activity. The most common cause of fungal infections in humans is Candida albicans. The most frequent cause of fungal urinary tract infections (UTIs) is Candida species. Candida UTIs can develop in the lower urinary tract or, in rare circumstances, even reach the kidneys. Fluconazole, an antifungal medication, has several applications. The incidence of VVC has surged as a result of rising diabetes occurrences and people's recurrent use of antibiotics.

June 2021: In June 2021, Scynexis Inc. said that it was conducting Phase 3 clinical studies for IBREXAFUNGERP and Fluconazole tablets. A Phase 3 clinical trial was carried out at several locations for this study. This research compares the safety and efficacy of oral ibrexafungerp (formerly known as "SCY-078") versus a placebo in a randomized, double-blind fashion. The study focuses on female volunteers with recurrent vulvovaginal candidiasis (RVVC) who are 12 years of age or older.

September 2021: In September 2021, Ege University announced a study of the Phase 3 clinical trials for GynomaxÂ® XL Vaginal Ovule and EVEGYN A. This multicenter, randomized study assessed the safety and effectiveness of GynomaxÂ® XL ovule in treating trichomonal vaginitis, bacterial vaginosis, candidal vulvovaginitis, and mixed vaginal infections.

Vulvovaginal Candidiasis Treatment Market

Market Opportunities and Challenges

Candal vaginitis, often known as candidal vulvovaginitis (CVV), is the usual term for vaginal yeast infection. The number of instances of yeast infections has increased due to an increase in the worldwide burden of many illnesses, including cancer, neurological, gastrointestinal, and cardiovascular disorders. This has also increased the use of broad-spectrum antibiotics. The need for bacterial vulvovaginal candidiasis therapy is being driven by the quick rise in the worldwide illness burden, the growing incidence of hospital-acquired infections, and the growing need for improved treatment alternatives. Significant potential for the treatment of vulvovaginal candidiasis are also being created by the availability of pharmaceutical medications, the development of substantial technical developments in the biopharmaceutical industry, and the rising healthcare infrastructure in developing nations. Unawareness of Treatment Options for Vulvovaginal Candidiasis Despite the wide range of applications for vulvovaginal candidiasis treatments, the market is expected to face some challenges in its growth throughout the projection period.The expansion of the industry may be restricted by the lack of knowledge among individuals in emerging nations. Furthermore, the market is anticipated to be constrained by the lack of familiarity with sophisticated technologies and the high cost of diagnostic and treatment procedures

Get more information on this report: Download Free Sample PDF

Market Competitive Landscape

There are several well-known competitors fighting for market share in the fiercely competitive vulvovaginal candidiasis treatment industry. Major players in the industry include producers of natural products, generic medicine makers, and pharmaceutical behemoths. To increase their market share, these companies concentrate on product launches, mergers and acquisitions, and research and development initiatives. Furthermore, strategic alliances and partnerships with healthcare providers help them broaden their product offerings and geographic scope. Key players are Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Cadila Pharmaceuticals, Dr Reddyâ€™s Laboratories Ltd., Grupo Ferrer Internacional S.A, Glenmark Pharmaceuticals Ltd., Zydus Cadila.

Scope of the Report:

Report Metric	Details
Market size available for years	2019-2032
Base year considered	2021
Forecast period	2022-2032
Segments covered	By Type, By Drug Class, By Route of Administration, By Distribution Channel.
Regions covered	North America, Asia-Pacific, Latin America, Middle East & Africa and Europe
Companies Covered	Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Cadila Pharmaceuticals, Dr Reddyâ€™s Laboratories Ltd., Grupo Ferrer Internacional S.A, Glenmark Pharmaceuticals Ltd., Zydus Cadila

COVID-19 Impact on Global Vulvovaginal Candidiasis Treatment Market

The market for vulvovaginal candidiasis treatments was affected by the COVID-19 pandemic in many ways. Prescription medicine availability was impacted by supply chain and healthcare resource interruptions, even as the demand for over-the-counter antifungal treatments grew due to the growing emphasis on personal cleanliness and self-care practices. During the epidemic, telemedicine and remote consultations became practical choices for people in need of guidance and medication. Because of all these factors, the market for vulvovaginal candidiasis rebounded swiftly from the first quarter of covid and is expected to continue growing.

Key Target Audience:

Patients with Recurrent Infections
Healthcare Providers
Pharmacies and Pharmacists
Health Insurance Companies
Online Health Communities
Telehealth Providers
Medical Researchers and Academics
Pharmaceuticals Companies
Regulatory Bodies
Public Health Organizations

Our in-depth analysis of the Vulvovaginal Candidiasis Treatment Market includes the following segments:

By Type:	Acute Vulvovaginal Candidiasis Recurrent Vulvovaginal Candidiasis Severe Vulvovaginal Candidiasis Non-Albicans Vulvovaginal Candidiasis
By Drug Class:	Clotrimazole Nystatin Fluconazole Ketoconazole Terbinafine Terconazole Others
By Route of Administration:	Oral Intravenous Topical
By Distribution Channel:	Hospital Pharmacy Retail Pharmacy Online Pharmacy

Key Topics Covered in the Report:

Global Vulvovaginal Candidiasis Treatment Market Size (FYâ€™2022-FYâ€™2032)
Overview of Global Vulvovaginal Candidiasis Treatment Market
Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Type (Acute Vulvovaginal Candidiasis, Recurrent Vulvovaginal Candidiasis, Severe Vulvovaginal Candidiasis, Non-Albicans Vulvovaginal Candidiasis.)
Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Drug Class (Clotrimazole, Nystatin, Fluconazole, Ketoconazole, Terbinafine, Terconazole, Others).
Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Route of Administration (Oral, Intravenous, Topical)
Segmentation of Global Vulvovaginal Candidiasis Treatment Market By Distributional Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy)
Statistical Snap of Global Vulvovaginal Candidiasis Treatment Market
Expansion Analysis of Global Vulvovaginal Candidiasis Treatment Market
Problems and Obstacles in Global Vulvovaginal Candidiasis Treatment Market
Competitive Landscape in the Global Vulvovaginal Candidiasis Treatment Market
Impact of COVID-19 and Demonetization on Global Vulvovaginal Candidiasis Treatment Market
Details on Current Investment in Global Vulvovaginal Candidiasis Treatment Market
Competitive Analysis of Global Vulvovaginal Candidiasis Treatment Market
Prominent Players in the Global Vulvovaginal Candidiasis Treatment Market
SWOT Analysis of Global Vulvovaginal Candidiasis Treatment Market
Global Vulvovaginal Candidiasis Treatment Market Future Outlook and Projections (FYâ€™2022-FYâ€™2032)
Recommendations from Analyst

1. Introduction

1.1. Scope of the report
1.2. Market segment analysis

2. Research Methodology

2.1. Research data source
2.1.1. Secondary Data
2.1.2. Primary Data
2.1.3. SPERâ€™s internal database
2.1.4. Premium insight from KOLâ€™s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation

3. Executive Summary

4. Market Dynamics

4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers
4.1.2. Restraints
4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global Vulvovaginal Candidiasis Treatment Market.

5. Market variable and outlook

5.1. SWOT Analysis
5.1.1. Strengths
5.1.2. Weaknesses
5.1.3. Opportunities
5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape
5.2.2. Economic Landscape
5.2.3. Social Landscape
5.2.4. Technological Landscape
5.2.5. Environmental Landscape
5.2.6. Legal Landscape
5.3. PORTERâ€™s Five Forces
5.3.1. Bargaining power of suppliers
5.3.2. Bargaining power of buyers
5.3.3. Threat of Substitute
5.3.4. Threat of new entrant
5.3.5. Competitive rivalry
5.4. Heat Map Analysis

6. Competitive Landscape

6.1. Global Vulvovaginal Candidiasis Treatment Market Manufacturing Base Distribution, Sales Area, Product Type
6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global Vulvovaginal Candidiasis Treatment Market

7. Global Vulvovaginal Candidiasis Treatment Market, By Type (USD Million) 2019-2032

7.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Type, 2019-2025
7.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Type, 2026-2032
7.3. Acute Vulvovaginal Candidiasis
7.4. Recurrent Vulvovaginal Candidiasis
7.5. Severe Vulvovaginal Candidiasis
7.6. Non-Albicans Vulvovaginal Candidiasis

8. Global Vulvovaginal Candidiasis Treatment Market, By Drug Class (USD Million)2019-2032

8.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Drug Class, 2019-2025
8.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Drug Class, 2026-2032
8.3. Clotrimazole
8.4. Nystatin
8.5. Fluconazole
8.6. Ketoconazole
8.7. Terbinafine
8.8. Terconazole
8.9. Others

9. Global Vulvovaginal Candidiasis Treatment Market, By Route of Administration(USD Million)2019-2032

9.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Route of Administration, 2019-2025
9.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Route of Administration, 2026-2032
9.3. Oral
9.4. Intravenous
9.5. Topical

10. Global Vulvovaginal Candidiasis Treatment Market, By Distribution Channel (USD Million)2019-2032

10.1. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Distribution Channel, 2019-2025
10.2. Global Vulvovaginal Candidiasis Treatment Market Size, Share and Forecast, By Distribution Channel, 2026-2032
10.3. Hospital Pharmacy
10.4. Retail Pharmacy
10.5. Online Pharmacy

11. Global Vulvovaginal Candidiasis Treatment Market Forecast, 2019-2032 (USD Million)

11.1. Global Vulvovaginal Candidiasis Treatment Market Size and Market Share

12. Global Vulvovaginal Candidiasis Treatment Market, By Region, 2019-2032 (USD Million)

12.1. Global Vulvovaginal Candidiasis Treatment Market Size and Market Share By Region (2019-2025)
12.2. Global Vulvovaginal Candidiasis Treatment Market Size and Market Share By Region (2026-2032)
12.3. Asia-Pacific
12.3.1. Australia
12.3.2. China
12.3.3. India
12.3.4. Japan
12.3.5. South Korea
12.3.6. Rest of Asia-Pacific
12.4. Europe
12.4.1. France
12.4.2. Germany
12.4.3. Italy
12.4.4. Spain
12.4.5. United Kingdom
12.4.6. Rest of Europe
12.5. Middle East and Africa
12.5.1. Kingdom of Saudi Arabia
12.5.2. United Arab Emirates
12.5.3. Qatar
12.5.4. South Africa
12.5.5. Egypt
12.5.6. Morocco
12.5.7. Nigeria
12.5.8. Rest of Middle East & Africa
12.6. North America
12.6.1. Canada
12.6.2. Mexico
12.6.3. United States
12.7. Latin America
12.7.1. Argentina
12.7.2. Brazil
12.7.3. Rest of Latin America

13. Company Profile

13.1. Alembic Pharmaceuticals Limited
13.1.1. Company details
13.1.2. Financial outlook
13.1.3. Product summary
13.1.4. Recent developments
13.2. Accord Healthcare Ltd.
13.2.1. Company details
13.2.2. Financial outlook
13.2.3. Product summary
13.2.4. Recent developments
13.3. Aurobindo Pharma Limited
13.3.1. Company details
13.3.2. Financial outlook
13.3.3. Product summary
13.3.4. Recent developments
13.4. Bristol-Myers Squibb Company
13.4.1. Company details
13.4.2. Financial outlook
13.4.3. Product summary
13.4.4. Recent developments
13.5. Basilea Pharmaceuticals Ltd.
13.5.1. Company details
13.5.2. Financial outlook
13.5.3. Product summary
13.5.4. Recent developments
13.6. Cadila Pharmaceuticals
13.6.1. Company details
13.6.2. Financial outlook
13.6.3. Product summary
13.6.4. Recent developments
13.7. Dr Reddyâ€™s Laboratories Ltd.
13.7.1. Company details
13.7.2. Financial outlook
13.7.3. Product summary
13.7.4. Recent developments
13.8. Grupo Ferrer Internacional S.A
13.8.1. Company details
13.8.2. Financial outlook
13.8.3. Product summary
13.8.4. Recent developments
13.9. Glenmark Pharmaceuticals Ltd.
13.9.1. Company details
13.9.2. Financial outlook
13.9.3. Product summary
13.9.4. Recent developments
13.10. Zydus Cadila
13.10.1. Company details
13.10.2. Financial outlook
13.10.3. Product summary
13.10.4. Recent developments
13.11. Others

14. Conclusion

15. List of Abbreviations

16. Reference Links

SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.

The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.

SPER-Methodology-1

SPER-Methodology-2

SPER-Methodology-3

Frequently Asked Questions About This Report

What is the growth rate of the Vulvovaginal Candidiasis Treatment Market?

The Vulvovaginal Candidiasis Treatment Market grew in market size from 2021. The Market is expected to reach USD 1.62 billion by 2032, at a CAGR of 4.61% during the forecast period.

What is the anticipated CAGR of the Vulvovaginal Candidiasis Treatment Market during the forecast period?

The Vulvovaginal Candidiasis Treatment Market CAGR of 4.61% during the forecast period.

How can I get the sample report on the Vulvovaginal Candidiasis Treatment Market?

You can get the sample pages by clicking the link -Click Here

What is the market size of the Vulvovaginal Candidiasis Treatment Market?

The Vulvovaginal Candidiasis Treatment Market size is USD 1.62 billion from 2022 to 2032.

Which segment is expected to lead the Vulvovaginal Candidiasis Treatment Market the forecast period?

The Vulvovaginal Candidiasis Treatment Market segment is Covered By Drug Class, By Route of Administration, By Distribution Channel.

Which region is expected to have the highest market share in the Vulvovaginal Candidiasis Treatment Market?

The North America and Europe region is anticipated to have the highest market share in the Vulvovaginal Candidiasis Treatment Market.

Who are the key players in Vulvovaginal Candidiasis Treatment Market?

The key players in the market include Companies Covered Alembic Pharmaceuticals Limited, Accord Healthcare Ltd., Aurobindo Pharma Limited, Bristol-Myers Squibb Company, Basilea Pharmaceuticals Ltd., Cadila Pharmaceuticals, Dr Reddy’s Laboratories Ltd., Grupo Ferrer Internacional S.A, Glenmark Pharmaceuticals Ltd., Zydus Cadila.

What is the conclusion of the Vulvovaginal Candidiasis Treatment Market?

The most common cause of fungal infections in humans is Candida albicans. The most frequent cause of fungal urinary tract infections (UTIs) is Candida species.

How big is the Vulvovaginal Candidiasis Treatment Market?

The Vulvovaginal Candidiasis Treatment Market is projected to reach USD 1.62 billion by 2032, growing at a CAGR of 4.61% during the forecast period.